Immatics (NASDAQ:IMTX) Shares Sold by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC decreased its holdings in shares of Immatics (NASDAQ:IMTX) by 27.4% during the 3rd quarter, Holdings Channel.com reports. The firm owned 13,155 shares of the company’s stock after selling 4,956 shares during the period. Exchange Traded Concepts LLC’s holdings in Immatics were worth $150,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Quarry LP acquired a new position in shares of Immatics in the 2nd quarter valued at $99,000. Forefront Analytics LLC acquired a new position in Immatics in the second quarter valued at $139,000. Nan Fung Group Holdings Ltd acquired a new position in Immatics in the first quarter valued at $165,000. AlphaCentric Advisors LLC grew its position in Immatics by 14.3% during the second quarter. AlphaCentric Advisors LLC now owns 20,000 shares of the company’s stock valued at $232,000 after acquiring an additional 2,500 shares during the period. Finally, Algert Global LLC acquired a new stake in Immatics during the second quarter worth about $242,000. 64.41% of the stock is currently owned by institutional investors and hedge funds.

Immatics Price Performance

Shares of IMTX stock opened at $9.54 on Wednesday. The firm has a market cap of $807.64 million, a P/E ratio of -9.00 and a beta of 0.75. The firm has a fifty day moving average of $11.16 and a two-hundred day moving average of $11.43. Immatics has a 1-year low of $7.15 and a 1-year high of $13.77.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.17. Immatics had a negative return on equity of 23.34% and a negative net margin of 103.99%. The firm had revenue of $20.19 million for the quarter, compared to analysts’ expectations of $12.36 million. On average, sell-side analysts expect that Immatics will post -0.94 EPS for the current year.

Analyst Upgrades and Downgrades

IMTX has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immatics in a research report on Thursday, September 5th. Piper Sandler started coverage on shares of Immatics in a research report on Monday, October 7th. They set an “overweight” rating and a $19.00 target price on the stock.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.